Britannia Establishes U.S. Consumer Products Division
18 Dec 2023
New cosmetic product safety regulations in the U.S. will usher in more stringent compliance and reporting requirements
ADSL to initially offer U.S. clients access to its technology-enabled safety and registration platform, as well as Responsible Person services
U.S. service offering to be enhanced with the addition of formulations, consumer trials, and artificial transdermal testing in early 2024
Toronto, Ontario and London, United Kingdom--(News - December 18, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia") is pleased to announce that its subsidiary, Advanced Development & Safety Laboratories ("ADSL"), has established a U.S.-based division ("ADSL USA") to assist companies in navigating the evolving cosmetic regulatory landscape in the U.S. The new division will also allow ADSL to better support its existing global customers in the U.S. market. The launch of ADSL USA underscores Britannia's commitment to expanding its geographic reach and providing enhanced services to cosmetics and consumer products clients globally.
The introduction of the Modernization of Cosmetics Regulation Act ("MoCRA") is the most significant expansion of the FDA's authority to regulate cosmetics since the Federal Food, Drug, and Cosmetic ("FD&C") Act was passed in 1938. This new law helps ensure the safety of cosmetic products that many consumers use daily, bringing reporting requirements to a similar standard as the EU and UK. ADSL, a recognized leader in formulation, testing, and overall regulatory compliance for the cosmetics industry, will be the partner of choice for foreign and U.S.-domiciled companies looking to adapt to the new U.S. regulations.
ADSL USA is committed to assisting clients in meeting regulatory requirements, ensuring product safety, timely approvals, and market access. The new division will offer a comprehensive suite of services, including Responsible Person support, product registration and labelling, and product safety reports, specifically tailored to help clients successfully manoeuvre through the regulatory requirements under MoCRA.
"We are excited to be at the forefront of MoCRA compliance, offering our clients unparalleled expertise and support in navigating the regulatory landscape," said Mark Bowes-Cavanagh, CEO of Britannia Global Consumer Products. "Our services are designed to streamline the compliance process, providing added trust and transparency to our clients and their customers."
Prospective customers and other interested parties are encouraged to contact:
Mark Bowes-Cavanagh
mark@britannia.life
About Britannia Life Sciences
Britannia Life Sciences Inc. is a company focused on introducing cutting-edge technologies into the traditional laboratory and regulatory platforms to power data-driven insights to improve the outcomes of its customers. Britannia provides services to the consumer products sector included an integrated suite of services to assist companies along their product development journey. Britannia's services, including product formulations, safety assessments, analytical and microbiological testing, global compliance, and consumer evaluations are offered to companies ranging from multinationals to start-ups particularly in the cosmetics, food, and wellness industries. Britannia also provides geochemical testing and analysis to the natural resources industry through its subsidiary Britannia Mining Solutions. Britannia's head office is located at 120 Adelaide Street West, Suite 2400, Toronto, Ontario, M5H 1T1.
For inquiries or more information on Britannia's growing suite of product development, analytical testing, regulatory and compliance solutions across a range of industries, please visit or contact:
Peter Shippen, CEO
Tel: +1 416 930 7711 or +44 738 744 7441
Email: peter@britannia.life
To view the source version of this press release, please visit
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.